Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

56%

5 trials in Phase 3/4

Results Transparency

150%

6 of 4 completed trials have results

Key Signals

1 recruiting6 with results

Enrollment Performance

Analytics

Phase 3

4(44.4%)

Phase 2

2(22.2%)

Phase 1

2(22.2%)

Phase 4

1(11.1%)

9Total

Phase 3(4)

Phase 2(2)

Phase 1(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06892639Phase 3Active Not Recruiting

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

Role: collaborator

NCT06014086Phase 1Active Not Recruiting

Intratumoral PH-762 for Cutaneous Carcinoma

Role: collaborator

NCT06830863Phase 1Recruiting

A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

Role: collaborator

NCT02527421Phase 3Terminated

DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis

Role: collaborator

NCT03179605Phase 2Terminated

Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06

Role: collaborator

NCT01947491Phase 3Completed

A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis

Role: collaborator

NCT01967069Phase 3Completed

A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis

Role: collaborator

NCT02749799Phase 4Completed

Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis

Role: collaborator

NCT02070965Phase 2Completed

DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

Role: collaborator

All 9 trials loaded